Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics $21.7 Million in Cash at End of Third Quarter Expected to Fund the Company Into the Third Quarter of 2025Top-Line Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH Expected in December of 2024Top-Line Data From the MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in the First Quarter ...